Formula F9
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
241 recalls, newest first
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations: FDA analysis found product to contain acetal and acetaldehyde above specification limits.
CGMP deviations
CGMP Deviations: Potential exposure to rodents and rodent activity in the distribution center.
cGmp Deviations
cGMP deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.
cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.
cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.
CGMP Deviations
CGMP Deviations